Science|Business and Sweden’s Karolinska Institutet have conducted a survey of a wide range of stakeholders in personalised healthcare across four major EU-markets (Belgium, France, the Netherlands and the UK).
Get your free copy
Science|Business and Sweden’s Karolinska Institutet have conducted a survey of a wide range of stakeholders in personalised healthcare across four major EU-markets (Belgium, France, the Netherlands and the UK). The story of personalised healthcare is a classic case of the difficulties of getting a game changing technology from lab to market. Specialists in the field agree: It is powerful, important, destabilising, disruptive. But a host of problems slow its deployment into mainstream medicine. Personalised medicine holds enormous potential, but European healthcare professionals foresee many problems to be overcome before that potential can be realised. This reports brings you the Karolinska survey’s key results, presented along with ideas which emerged from a discussion of the issues identified in the work.
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
